Benefit of adjuvant effect of a drug named dexmedetomidine given through nose during pituitary tumor resection surgeries

Efficacy of intranasal dexmedetomidine as an adjuvant during transnasal transsphenoidal pituitary tumor resection surgeries

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/07/026600

Enrollment

Registered

2020-07-15

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C719- Malignant neoplasm of brain, unspecified

Interventions

Intervention1: Dexmedetomidine(2microgram/kg in 12ml of normal saline ) vs normal saline(12ml Normal saline): Efficacy of adjuvant effect of dexmedetomidine on nasal mucosal is compared with normal sa

Eligibility

Inclusion criteria

Inclusion criteria: ASA physical status I and II, Patients scheduled for mTNTS surgery,

Exclusion criteria

Exclusion criteria: ASA physical status III and IV, BMI 30, GCS Patients with uncontrolled hypertension, Anticipated difficult airway

Design outcomes

Primary

Measure	Time frame
To evaluate the adjuvant effect of intranasal dexmedetomidine on nasal mucosal decongestion in patients undergoing mTNTS procedureTimepoint: Start of anesthesia to 2 hours in PACU	—

Secondary

Measure	Time frame
To assess the adjuvant effect of intranasal dexmedetomdine on incidence of hypertensive surge episodes and requirement of esmolol for management of these episodes in patients undergoing mTNTS surgeryTimepoint: Start of anesthesia to cessation of anesthesia	—

Countries

India

Contacts

Public ContactUzma Begum

GB Pant hospital

kirankiro@gmail.com9999088461

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026